Opendata, web and dolomites


Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control

Total Cost €


EC-Contrib. €






 BRCA-ERC project word cloud

Explore the words cloud of the BRCA-ERC project. It provides you a very rough idea of what is the project "BRCA-ERC" about.

immunologists    uncover    establishing    cells    identity    chronic    screening    medical    demonstrates    placed    cardiovascular    reset    reducing    cohort    pioneering    ideally    risk    carriers    extremely    buccal    overtaking    scientific    mutation    autonomous    cancer    effect    distant    possibly    cervical    controls    mechanistically    re    recent    germline    lack    outcome    applicable    efficacy    samples    tissues    net    normal    fundamental    epigenome    functionalists    origin    patient    interdisciplinary    mutations    blood    hypothesis    linked    monitor    core    human    advocacy    centered    cell    mortality    powerful    biologists    largely    medicine    fatal    trigger    groups    surgery    computational    principles    team    consequence    breakthrough    brca    assembled    clinician    consequently    cancers    newly    breast    predictors    direct    diseases    disease    ovarian    multicellular    preventative    initiating    epigenetic    multifactorial    brca1    women    neutralise    scientists    organs   

Project "BRCA-ERC" data sheet

The following table provides information about the project.


Organization address
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙497˙841 €
 EC max contribution 2˙497˙841 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 2˙264˙589.00


 Project objective

Recent evidence demonstrates that cancer is overtaking cardiovascular disease as the number one cause of mortality in Europe. This is largely due to the lack of preventative measures for common (e.g. breast) or highly fatal (e.g. ovarian) human cancers. Most cancers are multifactorial in origin. The core hypothesis of this research programme is that the extremely high risk of BRCA1/2 germline mutation carriers to develop breast and ovarian cancer is a net consequence of cell-autonomous (direct effect of BRCA mutation in cells at risk) and cell non-autonomous (produced in distant organs and affecting organs at risk) factors which both trigger epigenetic, cancer-initiating effects. The project’s aims are centered around the principles of systems medicine and built on a large cohort of BRCA mutation carriers and controls who will be offered newly established cancer screening programmes. We will uncover how ‘cell non-autonomous’ factors work, provide detail on the epigenetic changes in at-risk tissues and investigate whether these changes are mechanistically linked to cancer, study whether we can neutralise this process and measure success in the organs at risk, and ideally in easy to access samples such as blood, buccal and cervical cells. In my Department for Women’s Cancer we have assembled a powerful interdisciplinary team including computational biologists, functionalists, immunologists and clinician scientists linked to leading patient advocacy groups which is extremely well placed to lead this pioneering project to develop the fundamental understanding of cancer development in women with BRCA mutations. To reset the epigenome, re-establishing normal cell identity and consequently reducing cancer risk without the need for surgery and being able to monitor the efficacy using multicellular epigenetic outcome predictors will be a major scientific and medical breakthrough and possibly applicable to other chronic diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRCA-ERC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRCA-ERC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Power of Randomness and Continuity in Submodular Optimization

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

Neurovulnerability (2019)

Molecular mechanisms underlying selective neuronal death in motor neuron diseases

Read More